Wang Ranran, Shi Ying, Chen Ling, Jiang Yiqun, Mao Chao, Yan Bin, Liu Shuang, Shan Bin, Tao Yongguang, Wang Xiang
Department of Thoracic and Cardiovascular Surgery, Second Xiangya Hospital of Central South University, Changsha, China.
Cancer Research Institute, Central South University, Changsha, Hunan, 410078 China.
Sci Rep. 2015 Dec 11;5:17826. doi: 10.1038/srep17826.
The lncRNA HOTAIR is a critical regulator of cancer progression. Chromatin remodeling factor LSH is critical for normal development of plants and mammals. However, the underlying mechanisms causing this in cancer are not entirely clear. The functional diversification of the FOXA1 and FOXA2 contributes to the target genes during evolution and carcinogenesis. Little is known about the ratio of FOXA1 to FOXA2 in cancer. We here found that both HOTAIR and LSH overexpression was significantly correlated with poor survival in patients with lung adenocarcinoma cancer (ADC). Also, the ratio of FOXA1 and FOXA2 is linked with poor survival in patients with lung ADC. HOTAIR regulates the ratio of FOXA1 to FOXA2 and migration and invasion. HOTAIR and the ratio of FOXA1 to FOXA2 are negatively correlated. HOTAIR knockdown inhibits migration and invasion. HOTAIR is associated with LSH, and this association linked with the binding of LSH in the promoter of FOXA1, not FOXA2. Targeted inhibition of HOTAIR suppresses the migratory and invasive properties. These data suggest that HOTAIR is an important mediator of the ratio of FOXA1 and FOXA2 and LSH involves in, and suggest that HOTAIR inhibition may represent a promising therapeutic option for suppressing lung ADC progression.
长链非编码RNA HOTAIR是癌症进展的关键调节因子。染色质重塑因子LSH对植物和哺乳动物的正常发育至关重要。然而,癌症中导致这种情况的潜在机制尚不完全清楚。FOXA1和FOXA2的功能多样化在进化和致癌过程中对靶基因有贡献。关于癌症中FOXA1与FOXA2的比例知之甚少。我们在此发现,HOTAIR和LSH的过表达均与肺腺癌(ADC)患者的不良生存显著相关。此外,FOXA1与FOXA2的比例与肺ADC患者的不良生存相关。HOTAIR调节FOXA1与FOXA2的比例以及迁移和侵袭。HOTAIR与FOXA1与FOXA2的比例呈负相关。HOTAIR敲低抑制迁移和侵袭。HOTAIR与LSH相关,这种关联与LSH在FOXA1而非FOXA2启动子中的结合有关。靶向抑制HOTAIR可抑制迁移和侵袭特性。这些数据表明,HOTAIR是FOXA1与FOXA2比例的重要调节因子,LSH参与其中,提示抑制HOTAIR可能是抑制肺ADC进展的一种有前景的治疗选择。